Background: Cervical cancer, nearly all cases of which are caused by one of several high-risk strains of the human papillomavirus (hr-HPV), leads to significant morbidity and mortality in individuals with a cervix. Trans masculine (TM) individuals were born with female reproductive organs and identify as male, man, transgender man, or another diverse gender identity different from their female assigned sex at birth. Routine preventive sexual health screening of TM patients is recommended, including screening for cervical cancer and other sexually transmitted infections (STIs); however, as many as one in three TM patients are not up-to-date per recommended U.S. guidelines. Among cisgender (non-transgender) women, self-swab hr.-HPV DNA testing as a primary cervical cancer screening method and self-swab specimen collection for other STIs have high levels of acceptability. No study has yet been conducted to compare the performance and acceptability of self-and provider-collected swabs for hr.-HPV DNA testing and other STIs in TM patients. Methods: This article describes the study protocol for a mixed-methods biobehavioral investigation enrolling 150 sexually active TM to (1) assess the clinical performance and acceptability of a vaginal self-swab for hr.-HPV DNA testing compared to provider cervical swab and cervical cytology, and (2) gather acceptability data on self-collected specimens for other STIs. Study participation entails a one-time clinical visit at Fenway Health in Boston, MA comprised of informed consent, quantitative assessment, venipuncture for syphilis testing and HIV (Rapid OraQuick) testing, randomization, collection of biological specimens/biomarkers, participant and provider satisfaction survey, and qualitative exit interview. Participants are compensated $100. The primary study outcomes are concordance (kappa statistic) and performance (sensitivity and specificity) of self-collected vaginal HPV DNA specimens vs provider-collected cervical HPV swabs as a gold standard.
Background
Cervical cancer is caused by a sexually transmitted infection with one of several high-risk strains of the human papillomavirus (hr-HPV) in 99.7% of cases [1] . This and other sexually transmitted infections (STIs) lead to significant morbidity and mortality in U.S. cisgender (i.e., non-transgender) females, with 10 million incident STI infections diagnosed annually [2] [3] [4] . HPV, a virus passed through direct genital contact, is the most common STI in the U.S. and the cause of virtually all cervical cancers [5] ; the estimated prevalence of high-risk oncogenic HPV among cisgender female adolescents and adults is 23%, and approximately 12,500 cases of cervical cancer are diagnosed each year [3] . Papanicolaou (Pap) cytologic testing is recommended to screen for cervical abnormalities in individuals with a cervix ages 21-65 years, with screening every 3 years if Pap test results are normal ("negative" result). HPV co-testing with Pap testing every 5 years is preferred for cisgender females ages 30 years and older. Screening for other STIs (HIV, syphilis, gonorrhea, chlamydia, trichomoniasis, bacterial vaginosis) is also recommended for all patients who engage in high-risk sexual behaviors [2] .
Despite myths that masculine-spectrum transgender people (trans masculine people; TM)individuals assigned a female sex at birth who identify as male, man, trans man, or another diverse gender identity not corresponding to their assigned female sex at birth [6] are at low risk for STIs, recent research shows that TM patients are at no lower risk for STIs and for cervical abnormalities as compared to cisgender women [7, 8] . Many TM individuals engage in sexual activity with sexual partners of diverse genders (including cisgender men and women, other TM individuals, and transgender women) and have multiple concurrent partners [9] ; engage in condomless receptive vaginal and/or anal sex with cisgender men [10] ; and demonstrate high rates of STI diagnosis, despite low rates of screening [11] .
As the majority (>80%) of TM do not undergo gender affirming genital surgery and therefore retain their cervix, American Congress of Obstetricians and Gynecologists (ACOG) recommend that these TM follow the same cervical cancer screening guidelines as cisgender women [12] , and undergo routine screening for other STIs [13] . Despite these recommendations, TM patients appear to be less likely to be current for cervical cancer screening than cisgender women [14, 15] . TM face multilevel barriers to undergoing cervical cancer screening, most notably discrimination by healthcare providers and insurance providers, leading to postponement of care [16] . Structural barriers to regular cervical screening include female-only waiting rooms, woman-centered and heteronormative patient education materials, and language from providers during the screening exam (e.g., "vagina", "panties")all of which fail to recognize and affirm participants' masculine gender identity [7] . Intrapersonal barriers to testing include a disconnect between birth-assigned sex and self-identified gender; desire to ignore the existence of natal reproductive structures; lack of knowledge that the cervix may be retained after some approaches to hysterectomy; high prevalence of past sexual or emotional trauma; heightened anxiety about having a genital exam; and fear of discrimination on the basis of being transgender [17] [18] [19] [20] [21] [22] [23] . Further, TMspecific physiological factors may also impact screening. Long-term testosterone therapy may induce vaginal atrophy and decreased lubrication [21, 23] , which may cause physical discomfort with the speculum exam. When TM patients do engage in cervical cancer screening, approximately 11% of Pap specimens in this patient population are found to be inadequate for analysis, as opposed to just 1.3% of tests in comparable cisgender women [7] . There is some evidence of a positive association between increasing rates of inadequate Pap specimens and length of time on testosterone [7] . Patient-centered research is needed to address these structural, intrapersonal, and clinical barriers that are driving low rates of screening in this stigmatized and at-risk patient population.
Self-collected hr.-HPV DNA testing as a primary cervical cancer screening technique [24] [25] [26] and self-swabs for STI testing [27] [28] [29] [30] [31] [32] [33] have been tested in hard-to-reach nontransgender female patients who are unlikely to engage in provider-administered screening. This methodology involves the use of a cotton-or polyester-tipped swab by a patient to self-collect a sample from the vaginal canal, without the use of a speculum. High-risk HPV DNA testing as a primary screening strategy for cervical cancer has been found in one study to have superior sensitivity compared to the current standard of care of cytologic screening alone or a hybrid screening strategy of cytology/h-HPV cotesting [26] . Additional studies have also found selfcollected vaginal specimens for primary hr.-HPV screening to be more acceptable than cervical cytologic screening among cisgender females due to the less invasive nature of self-collection, which in turn lead to increased adherence to screening recommendations in underscreened populations [24, 25, 34] . This modality also represents a potential approach to bridging barriers to screening among TM populations, as it minimizes or eliminates barriers such as pain during speculum exam, prevalent cytological inadequacy, and fear of negative interactions with providers during a pelvic exam. No studies have yet been conducted administering these tests and exploring their acceptability and clinical performance among TM patients.
The aims of this study were to 1) quantitatively and qualitatively assess the acceptability and clinical performance of a vaginal self-swab for hr.-HPV DNA testing compared to provider hr.-HPV and cervical cytologic cotesting among sexually active TM, and 2) investigate the prevalence of other STIs among sexually active TM. This study addresses critical gaps in current clinical knowledge of sexual health in TM patients, including comparing alternative strategies for prevention, screening, and diagnosis. We hypothesized that our findings would improve patient care, including attitudes about and comfort with screening, and delivery of preventive sexual health screening in this overlooked and underserved patient population, including potentially lessinvasive, alternative screening strategies for TM patients.
Methods & design

Design
This biobehavioral mixed-methods study examined preventive sexual health screening in 150 TM patients in Boston, MA. Community-based participatory research principles (CBPR) [35, 36] were employed throughout the study. A 10-member project-specific Task Force comprised of TM patients, providers, and stakeholders was established. The Task Force was comprised of 60% TM individuals who were recruited via referrals from Fenway staff and other TM community members. The Task Force met every other month (6 times per year) to provide input on all aspects of study design and conduct. Members were compensated $50 per meeting for their time. The Task Force developed a mission statement and bylaws that emphasized reciprocal relationships, colearning, partnership, trust, transparency, and honesty with all members of the study team, including investigators, staff, patients, providers, and stakeholders.
Setting
This study was conducted at The Fenway Institute at Fenway Health in Boston, MA. As of 2013, Fenway Health had approximately 650 TM patients actively engaged in medical care; by 2016 that number had increased to over 950 TM patients. All data were collected between April 2015 and September 2016. All study procedures were approved by the Fenway Health Institutional Review Board (FWA00000145).
Characteristics of participants
Individuals were eligible to participate in the one-time clinical study visit if they met the following criteria: 1) Ages 21-64 years (consistent with current cervical cancer screening recommendation); 2) Assigned a female sex at birth and now identifies a man, trans man, male, trans masculine, FTM (female-to-male), transgender, genderqueer/non-binary, transsexual, and/or another diverse transgender identity; 3) Have a cervix; 4) Sexually active in the past 36 months (with partner(s) of any gender); 5) Able to speak and understand English; and 6) Willing and able to provide informed consent.
Note on HPV vaccination
The research team considered excluding individuals who had received the HPV vaccine, but decided to enroll individuals regardless of HPV vaccination status for the following reasons: 1) current cervical cancer screening guidelines are identical for HPV vaccinated and unvaccinated individuals; 2) in our formative qualitative work, 62% reported never having received any dose of the HPV vaccination (unpublished data); 3) some TM individuals who are vaccinated will not have been vaccinated until after sexual debut and may have already been exposed to HPV; 4) there is a substantial risk of recall bias when relying on HPV vaccination self-report, especially series completion; 5) given the relatively recent introduction of routine HPV vaccination recommendations, it is far less likely for our subjects over the age of 30 years to have received a vaccination series; and 6) no research has reported prevalence of HPV vaccination in TM individuals, thus collecting information about HPV vaccination and number of doses completed would be a valuable aspect of the study.
Note on enrolling individuals who are up-to-date on cervical cancer screening
The research team considered whether to enroll participants self-reporting a Pap test in the prior 3 years, as this would in reality represent over-screening. Ultimately, the research team decided to enroll individuals regardless of self-report of last screening date or result, as self-report of last date of cervical cancer screening has been shown to be an inaccurate measure of actual screening utilization [37] [38] [39] . Participants were educated on the potential risks associated with over-screening (i.e., potentially unnecessary further testing such as colposcopy) during the informed consent process.
Study procedures Recruitment
Multiple convenience and referral-based sampling techniques were used by study staff to identify and recruit potentially eligible participants from the catchment area of Fenway Health's five clinics. Purposive sampling techniques were also used to ensure a diverse study sample with regards to age, race, and ethnicity. All recruitment was conducted by study staff who are also members of the TM community or allies.
Active recruitment was conducted by working with the Fenway Health data informatics team to identify patients coming in for routine care who were potentially eligible for the study through the electronic medical record. Staff asked providers to provide information about the study to patients identified as potential participants, as well as a card containing contact information for the study.
Potential participants were also recruited passively via the posting of study flyers at Fenway Health locations, as well as at community spaces frequented by TM individuals. Recruitment advertisements were posted to online platforms such as the Fenway research website, MyFenway and MyBorum (Fenway Health patient portals), Facebook, transgender community list serves, paid advertisements on Apps such as Scruff and FetLife, and in other local media such as the 2016 Boston Pride Guide. A study-specific website and a Facebook page were also developed to aid in recruitment and dissemination of information about the study.
Screening for eligibility
Individuals interested in participating consented to eligibility screening prior to enrollment. All study visits occurred within 1 month of screening. When scheduling the study visit, eligible individuals were given the option of seeing either a cisgender male or cisgender female study provider, and told that they had the option of bringing a support person into the exam room during the Pap test to help the participant feel more comfortable. (1)Informed Consent & Intake Paperwork -Written informed consent was obtained from each participant prior to the initiation of study procedures or assessments. (2)Self-Administered Quantitative Survey -All participants completed a quantitative assessment via computer-assisted interview technology (CASI) via a touch-screen iPad in self-administered format to increase the accurate reporting of sensitive questions (e.g., sexual behaviors, STI history) [40, 41] . To minimize cultural bias and maximize appropriateness and comparability to other research studies, we selected measures that were previously tested with diverse populations (including transgender people) whenever possible. See Table 1 for a full list of measures included in the quantitative assessment. There were three scenarios in which a participant did not need to undergo HIV testing: 1) the participant did not consent to the test, 2) the participant was HIV-infected and can provide documentation, and 3) the participant had been tested for HIV in the last 2 months and could provide sufficient documentation of their HIVnegative status (e.g., letter from the participant's provider/testing counselor, lab report). (4)Randomization -To guard against potential specimen collection ordering effects, participants were randomized to do either self-or providercollection first. Participants did not have an option as to which order specimen collection was done. A randomization table was generated using Statistical Analysis Software (SAS) Version 9.4.
Clinical visit procedures
(5)Collection of Biological Specimens -See Table 2 for a listing of all specimens collected during the onetime clinical visit and mode of collection (i.e., self-or provider-collected). See Tables 3 and 4 for collection materials and analysis of self-collected and providercollected specimens, respectively. provided an instruction sheet for reference during self-collection (Additional file 1). Testing swabs and collection tubes were color coded to prevent confusion. Study staff remained available for assistance during the self-collection procedure. Once self-collection was complete, participants delivered the specimens to study staff, who then labeled and packaged the samples per performing laboratory guidelines. b. Provider-Collection Procedures. Multiple providers (two cisgender male, three cisgender female) were trained in specimen collection according to study protocol. The exam and collection process were standardized. Providers conducted a brief pre-exam assessment and medical history using a script adapted from the Center for Disease Control and Prevention's A Guide to Taking a Sexual Health History [42] (Additional file 2). In order to insure fidelity, evaluate consistency between the actual occurrences of the visit and what was documented by the study provider, and identify any interprovider variability that could confound results, some provider sessions were audio recorded; each study clinician had a minimum of 10 sessions recorded the recordings were reviewed by an offsite expert. The provider collected a pharyngeal swab for GC/CT testing.
Participants were given several procedural options to help reduce exam anxiety, such as self-insertion of the speculum with verbal guidance by the provider, lying feet flat on the exam table instead of using stirrups, and examining the various instruments to be used prior to the exam. The provider then inserted an appropriately sized speculum using water-soluble lubricant applied along the sides of the speculum, avoiding the tip [43] ; the use of lubricant in this population is important given the high prevalence of anxiety and vaginal atrophy; the use of manufacturer-specified lubricant does not interfere with cytologic testing essential and appropriate [44] . Additional supplies provided to each participant: Hand mirror, latex gloves, written self-collection instructions Collection kits for each specimen were color coded and numbered to match to the respective instruction sheet and to mitigate errors in sample packaging Interviews were conducted to qualitatively understand acceptability of different cervical cancer and STI screening technologies. Participants answered questions about comparative acceptability of self-collected vaginal swab for HPV vs. provider-collected vaginal swab for hr-HPV vs. cervical cytology alone, and self-vs. provider-collected swabs for other STIs. In order to evaluate acceptability and feasibility, patients were also queried on the perceived difficulty of self-swabs, in line with methods in prior qualitative studies [45] . Participants also answered questions on preference for and acceptability of different clinical algorithms in screening taking into consideration potential risks of over-screening (and need for colposcopy) when using a hr-HPV-only or hr-HPV-triage approach [26] . Lastly participants were asked general questions relating to study procedures.
A subsample of 50 participants were purposively sampled to undergo a more in-depth interview (additional 30 minute interview, additional $10 incentive). Participants were invited to undergo the longer interview to maximize diversity in demographics (age, gender identity, race/ethnicity, recent sexual behavior) as well as to maximize diversity of opinion as expressed in the first part of the interview (e.g., opinion on acceptability of the self-swabs). The in-depth qualitative interview covered the previously described exit interview topics as well as additional domains to inform future clinical practice and research: 1) narrative history of preventive sexual health screening; 2) barriers and facilitators to screening utilization guided by Health Belief Model constructs [46] ; 3) past and current experiences of stigma in accessing preventative sexual health screening guided by the "hidden distress" model [47] , including felt and enacted stigma; 4) acceptability of sexual health screening questions to inform further development of a clinical tool that can be used to standardize sexual and behavioral risk screening; 5) acceptability of biomedical prevention strategies in high-risk TMs, such as Pre-Exposure Prophylaxis (PrEP) for HIV prevention.
Statistical analysis
The primary outcome variables of the study are concordance (kappa statistic) and performance (sensitivity and specificity) of self-collected vaginal HPV DNA specimens vs provider-collected cervical HPV swabs as a gold standard. McNemar's test is a two-sample test for binomial proportions for matched-pair data [48] . An adjusted McNemar test [49] will be used to compare the proportions of hr.-HPV DNA-positive results between samples while accounting for the correlation of multiple samples within subjects [50] . This analytic approach has been used previously in hr.-HPV research assessing concordance of self/provider swabs [51] . The concordance of hr.-HPV DNA detection between sampling modalities will be assessed using an unweighted Kappa (K) statistic to determine the percentage agreement beyond that expected by chance [52] , and jackknife estimation will be used to compute the variance while accounting for correlation within subjects. Sensitivity, the probability of a positive test given that the individual has the condition, will be calculated as sensitivity = true positive/(true positive + false negative). Specificity, the probability of correcting detecting individuals without a condition, will be estimated as specificity = true negative/(true negative + false positive). selected a sample size of 150 to detect a 15% or more discordance between the two sampling approaches (and achieve 80% power at the 0.05 alpha-level. A meta-analysis of hr.-HPV self-swab studies found the range of absolute differences in detection rates between swab sampling methods (self vaginal, provider cervical) was most often between 0.14%-22.2% (median 19%) [53] .
Power and sample size
Qualitative analysis
Qualitative data will be analyzed using a combination of traditional content analysis [55] and techniques borrowed from grounded theory [56] . Transcripts will first be reviewed for errors and omissions, and identifying information will be redacted. Study staff will then open code a series of transcripts and group the open codes into a codebook according to themes. A team of two analysts will then individually code the transcripts using Dedoose software [57] . The analysts will meet regularly throughout the coding process to discuss emerging themes and add additional codes as needed. Coded data will be analyzed through ongoing discussion between coders and investigators to allow for interconnections between research questions, coding transcripts, and raw data [56] .
Discussion
This study addresses critical gaps in current clinical knowledge of sexual health in TM individuals. We are the first to our knowledge to describe rates of cervical high-risk HPV DNA infection and of STIs in a study focused specifically on TM individuals. We are also the first to our knowledge to examine the role and performance of self-collected hr.-HPV DNA testing as a primary cervical cancer screening strategy in TM individuals. Given evidence that self-collected hr.-HPV DNA testing may improve screening rates in underscreened populations of cisgender women [34] , this screening modality could prove critical in addressing screening disparities for TM individuals, if the clinical performance of the test is adequate. In addition to self-collected hr.-HPV DNA testing, findings may also support alternative patientcentered screening strategies for other STIs in TM individuals. This community-engaged, patient-centered research will allow providers to become better informed on approaches to caring for TM individuals, and has the potential to improve uptake of sexual health screening in this marginalized population. Findings have implications for delivery of preventive sexual healthcare screening in TM patients and may generalize to other at-risk cisgender female populations that face barriers to timely and needed STI and cervical cancer screening. The study can inform a future randomized controlled trial (RCT) of an intervention to test the efficacy of self-collected swabbing for hr.-HPV DNA testing and other STIs vs. usual clinical care to improve preventive sexual health screening uptake in TM patients. 
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